A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors
Completed · Phase 1 · Has a placebo group
Conditions studied: Cancer, Malignant Tumors
In brief
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 after bolus IV administration, on Day 1 of a 21-day cycle, to patients with advanced solid tumors that have progressed following effective therapy or for which no effective therapy exists.
Key facts
- Study ID
- NCT00165802
- Run by
- Eisai Inc.
- People needed
- 40
- Starts
- 2006-05-01
- Expected to finish
- 2009-01-01
- Last updated by the study team
- 2013-05-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sylvester Comprehensive Cancer Center - University of Miami — Miami, Florida, United States
- Cancer Institute Of New Jersey — New Brunswick, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.